The Corona Remedies IPO, a significant event in the Mainboard segment, has concluded its subscription period. Investors are now keenly watching the Corona Remedies IPO GMP (Grey Market Premium) to gauge the expected listing performance.
This comprehensive, SEO-optimized blog post provides the latest analysis of the Corona Remedies IPO GMP, along with all the official details, key dates, and a brief overview of the company's business.
Corona Remedies IPO GMP Status: Latest Updates
Focus Keyword: Corona Remedies IPO GMP
The Grey Market Premium (GMP) is an unofficial figure that helps investors estimate the potential listing price of an IPO. It indicates the premium at which the shares are traded in the private grey market.
Today's Corona Remedies IPO GMP: As of December 10, 2025 (the final day of subscription), the Corona Remedies IPO GMP is at ₹270.Estimated Listing Price: Based on the upper price band of ₹1062 and the current GMP of ₹270, the estimated listing price is ₹1332 (₹1062 + ₹270).
Expected Returns: This suggests a robust expected listing gain of approximately 25.42%.
GMP Trend Analysis: The GMP has seen some volatility, reaching a high of ₹365 earlier, but has settled around the ₹270 mark as the issue closed, which is still a strong premium for listing.
Corona Remedies IPO: Key Details and Timeline
Corona Remedies IPO is a Book Built Issue Mainboard IPO raising approximately ₹655.37 Crores, entirely through an Offer for Sale (OFS) of around 61,71,101 Equity Shares. The IPO will be listed on both BSE and NSE.
Important Investor Dates
Business Overview: Corona Remedies Limited
Founded in August 2004, Corona Remedies Limited is a leading pharmaceutical company in India, focusing on the manufacturing and sale of products across key therapeutic areas.
Market Position: It is reported to be the 2nd largest company among 30 others in the Indian Pharmaceutical Market (IPM) in certain segments.
Product Portfolio: The company manages 67 brands across various therapeutic areas, including:
Women's Healthcare
Cardio-Diabetology
Pain Management
Urology
Multi-Specialty Pharmaceuticals
Presence: Corona Remedies has a pan-India presence with 2,598 medical representatives across 22 states and operates two manufacturing facilities in Gujarat.
Market Lot and Investment Details
Retail investors could apply for a minimum lot size:
Final Verdict and Next Steps
The strong subscription figures (over 9.91x on Day 2) and a healthy Corona Remedies IPO GMP indicate robust demand for the company's shares. Given the strong financials and the booming pharmaceutical sector, this IPO is viewed positively by market experts for both short-term listing gains and long-term holding.
The next crucial step is the allotment finalization. Would you like me to find the link to check the allotment status once it is available on December 11, 2025?
Post a Comment